Nature Research

SHERPA: Unknown

People

  1. Weigelt
    Weigelt
  2. Pareja Zea
    Pareja Zea
  3. Ladanyi
    Ladanyi
  4. Brogi
    Brogi
  5. Basturk
    Basturk
  6. Travis
    Travis
  7. Wen
    Wen
  8. Antonescu
    Antonescu
  9. Shia
    Shia
  10. Jungbluth
    Jungbluth

Groups

  1. Sloan Kettering Institute Postdocs (230)
  2. Department of Pathology and Laboratory Medicine (191)
  3. GSK Faculty (138)
  4. Department of Medicine (76)
  5. GDMT, Pathology and Laboratory Medicine (70)
  6. Gynecology Disease Management Team (70)
  7. Center for Pancreatic Cancer Research (67)
  8. Solid Tumor Oncology Division (67)
  9. Surgery (66)
  10. Human Oncology and Pathogenesis Program (64)
Search Within
  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (135)
  2. Journal Article (90)
  3. Editorial (4)
  4. Review (1)
Groups
  1. Sloan Kettering Institute Postdocs (230)
  2. Department of Pathology and Laboratory Medicine (191)
  3. GSK Faculty (138)
  4. Department of Medicine (76)
  5. GDMT, Pathology and Laboratory Medicine (70)
  6. Gynecology Disease Management Team (70)

More Groups

People
  1. Britta Weigelt (63)
  2. Jorge Reis-Filho (57)
  3. Fresia Pareja Zea (34)
  4. David Klimstra (33)
  5. Felipe Correa Geyer (30)
  6. Marc Ladanyi (29)

More People

Years
  1. 2025 (5)
  2. 2024 (9)
  3. 2023 (13)
  4. 2022 (41)
  5. 2021 (17)
  6. 2020 (27)

More Years

Publications
  1. Modern Pathology (194)
  2. Nature Cancer (36)

Results (230)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies
    Journal Article

    Dobrin, A.; Lindenbergh, P. L.; Shi, Y.; Perica, K.; Xie, H.; Jain, N.; Chow, A.; Wolchok, J. D.; Merghoub, T.; Sadelain, M.; more...
    Nature Cancer (2024)

    Fulltext@MSK | Save
  • Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease
    Journal Article

    Leibold, J.; Tsanov, K. M.; Amor, C.; Ho, Y. J.; Sánchez-Rivera, F. J.; Feucht, J.; Baslan, T.; Chen, H. A.; Tian, S.; Simon, J.; more...
    Nature Cancer (2024)

    Fulltext@MSK | Save
  • Bacteria and bacteriophage consortia are associated with protective intestinal metabolites in patients receiving stem cell transplantation
    Journal Article

    Thiele Orberg, E.; Meedt, E.; Hiergeist, A.; Xue, J.; Heinrich, P.; Ru, J.; Ghimire, S.; Miltiadous, O.; Lindner, S.; Tiefgraber, M.; more...
    Nature Cancer (2024)

    Fulltext@MSK | Save
  • Nonlobular invasive breast carcinomas with biallelic pathogenic CDH1 somatic alterations: A histologic, immunophenotypic, and genomic characterization
    Journal Article

    Derakhshan, F.; Da Cruz Paula, A.; Selenica, P.; da Silva, E. M.; Grabenstetter, A.; Jalali, S.; Gazzo, A. M.; Dopeso, H.; Marra, A.; Brown, D. N.; more...
    Modern Pathology (2024)

    Fulltext@MSK | Save
  • Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia
    Journal Article

    Knorr, K.; Rahman, J.; Erickson, C.; Wang, E.; Monetti, M.; Li, Z.; Ortiz-Pacheco, J.; Jones, A.; Lu, S. X.; Stanley, R. F.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Journal Article

    Maura, F.; Boyle, E. M.; Coffey, D.; Maclachlan, K.; Gagler, D.; Diamond, B.; Ghamlouch, H.; Blaney, P.; Ziccheddu, B.; Cirrincione, A.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab emtansine therapy in recurrent high-grade endometrial cancer
    Journal Article

    Shen, S.; Ma, W.; Brown, D.; Da Cruz Paula, A.; Zhou, Q.; Iaosonos, A.; Tessier-Cloutier, B.; Ross, D. S.; Troso-Sandoval, T.; Reis-Filho, J. S.; more...
    Modern Pathology (2023)

    Fulltext@MSK | Save
  • Vepafestinib: a RET-selective inhibitor with enhanced CNS penetrance targets therapy-resistant mutants
    Editorial

    Odintsov, I.; Somwar, R.
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
    Journal Article

    Miyazaki, I.; Odintsov, I.; Ishida, K.; Lui, A. J. W.; Kato, M.; Suzuki, T.; Zhang, T.; Wakayama, K.; Kurth, R. I.; Cheng, R.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • The significance of International Federation of Gynecology and Obstetrics grading in microsatellite instability-high and POLE-mutant endometrioid endometrial carcinoma
    Journal Article

    Kertowidjojo, E.; Momeni-Boroujeni, A.; Rios-Doria, E.; Abu-Rustum, N.; Soslow, R. A.
    Modern Pathology (2023)

    Fulltext@MSK | Save

    • Nature Research – authorized name for: